摘要
天疱疮是一种严重的自身免疫性大疱病,部分病例对传统治疗的疗效不佳.近几年临床研究发现,利妥昔单抗可明显提高天疱疮患者的临床治愈率,且可获得长期缓解,复发后再次治疗的安全性与临床缓解率仍较理想.利妥昔单抗不仅适用于重症难治性天疱疮,也有治疗轻至中度甚至儿童天疱疮的相关报道.目前已有较多关于利妥昔单抗不同单次治疗剂量或总剂量使天疱疮病情缓解的报道.利妥昔单抗可联合用药提高临床缓解率,其在安全剂量内仍会出现相关不良反应.
Pemphigus is a serious autoimmune bullous disease,and some cases of pemphigus poorly respond to traditional treatments.In recent years,studies have shown that rituximab could significantly improve recovery rate in pemphigus patients with a long-term remission.Retreatment with rituximab following recurrence also can result in satisfactory clinical remission rates with favorable safety.Rituximab is not only suitable for severe refractory pemphigus,but also for mild,moderate,and even childhood pemphigus.There have been a lot of reports on the control of pemphigus with different therapeutic doses and total doses of rituximab.Rituximab can also be combined to improve clinical remission rate in patients,but drug-related adverse reactions can occur within its safe dose range.
出处
《国际皮肤性病学杂志》
2014年第6期356-359,共4页
International Journal of Dermatology and Venereology
